Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Trial Profile

Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms AFUGEM
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 30 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.
    • 10 Aug 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top